J. Andrade-Villanueva's Profile

Role	Title	Level	Year	L/R
🐜	Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials 24 auth. P. Sax, D. Wohl, M. Yin, F. Post, E. Dejesus, M. Saag, A. Pozniak, M. Thompson, D. Podzamczer, J. Molina, ... S. Oka, E. Koenig, B. Trottier, J. Andrade-Villanueva, G. Crofoot, J. Custodio, Andrew Plummer, Lijie Zhong, H. Cao, Hal Martin, C. Callebaut, A. Cheng, M. Fordyce, S. McCallister	9	2015	9 🐜
🐜	Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study 12 auth. J. Molina, J. Andrade-Villanueva, J. Echevarría, P. Chetchotisakd, J. Corral, Neal David, ... G. Moyle, M. Mancini, Lisa Percival, Rong Yang, A. Thiry, D. McGrath	8	2008	8 🐜
🐜	Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study 22 auth. P. Cahn, A. Pozniak, H. Mingrone, A. Shuldyakov, C. Brites, J. Andrade-Villanueva, G. Richmond, Carlos Beltrán Buendía, J. Fourie, M. Ramgopal, ... D. Hagins, F. Felizarta, J. Madruga, T. Reuter, T. Newman, C. Small, J. Lombaard, B. Grinsztejn, D. Dorey, M. Underwood, Sandy Griffith, S. Min	8	2013	8 🐜
🐜	Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 12 auth. Roberto Ortiz, E. Dejesus, H. Khanlou, Evgeniy Voronin, J. van Lunzen, J. Andrade-Villanueva, ... J. Fourie, S. De Meyer, M. de Pauw, E. Lefebvre, T. Vangeneugden, S. Spinosa‐Guzman	8	2008	8 🐜
🐜	Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial 12 auth. C. Cohen, J. Andrade-Villanueva, B. Clotet, J. Fourie, M. Johnson, K. Ruxrungtham, ... Hao Wu, C. Zorrilla, H. Crauwels, L. Rimsky, S. Vanveggel, K. Boven	8	2011	8 🐜
🐜	Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials 21 auth. J. Eron, B. Young, D. Cooper, M. Youle, E. Dejesus, J. Andrade-Villanueva, C. Workman, R. Zajdenverg, G. Fätkenheuer, D. Berger, ... Princy N. Kumar, A. Rodgers, M. Shaughnessy, Monica L Walker, Richard J. O. Barnard, Michael D. Miller, M. Dinubile, B. Nguyen, R. Leavitt, Xia Xu, P. Sklar	8	2010	8 🐜
🐜	Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. 27 auth. S. Swindells, J. Andrade-Villanueva, G. Richmond, G. Rizzardini, A. Baumgarten, M. Masiá, G. Latiff, V. Pokrovsky, Fritz Bredeek, Graham H R Smith, P. Cahn, Yeon-Sook Kim, S. Ford, C. Talarico, P. Patel, ... V. Chounta, H. Crauwels, W. Parys, S. Vanveggel, J. Mrus, Jenny Huang, Conn M. Harrington, Krischan J. Hudson, D. Margolis, Kimberly Smith, P. Williams, W. Spreen	8	2020	8 🐜
🐜	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. 22 auth. A. Mills, J. Arribas, J. Andrade-Villanueva, G. Diperri, J. van Lunzen, E. Koenig, R. Elion, M. Cavassini, J. Madruga, J. Brunetta, ... D. Shamblaw, E. Dejesus, C. Orkin, D. Wohl, I. Brar, J. Stephens, P. Girard, G. Huhn, Andrew Plummer, Yapei Liu, A. Cheng, S. McCallister	8	2016	8 🐜
🐜	Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study 14 auth. J. Molina, J. Andrade-Villanueva, J. Echevarría, P. Chetchotisakd, J. Corral, Neal David, G. Moyle, M. Mancini, Lisa Percival, Rong Yang, ... V. Wirtz, M. Lataillade, J. Absalon, D. McGrath	8	2010	8 🐜
🐜	Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. 24 auth. J. Eron, J. Rockstroh, J. Reynes, J. Andrade-Villanueva, J. V. Ramalho-Madruga, L. Bekker, B. Young, C. Katlama, J. M. Gatell-Artigas, J. Arribas, ... M. Nelson, Havilland Campbell, Jinrong Zhao, A. Rodgers, M. Rizk, L. Wenning, Michael D. Miller, D. Hazuda, M. Dinubile, R. Leavitt, R. Isaacs, M. Robertson, P. Sklar, B. Nguyen	7	2011	7 🐜
🐜	Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study 28 auth. E. Overton, G. Richmond, G. Rizzardini, H. Jaeger, C. Orrell, F. Nagimova, Fritz Bredeek, M. G. Deltoro, S. Swindells, J. Andrade-Villanueva, Alexander Wong, M. Khuong-Josses, R. V. Solingen-Ristea, V. V. Eygen, H. Crauwels, ... S. Ford, C. Talarico, P. Benn, Yuanyuan Wang, Krischan J. Hudson, V. Chounta, A. Cutrell, P. Patel, M. Shaefer, D. Margolis, Kimberly Smith, S. Vanveggel, W. Spreen	7	2020	7 🐜
🐜	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial 33 auth. Jordana B. Cohen, T. Hanff, Preethi William, N. Sweitzer, Nelson R Rosado-Santander, Carola Medina, Juan E Rodriguez-Mori, Nicolás Renna, T. Chang, V. Corrales-Medina, J. Andrade-Villanueva, Alejandro Barbagelata, Roberto Cristodulo-Cortez, Omar A Díaz-Cucho, J. Spaak, ... C. Alfonso, Renzo Valdivia-Vega, Mirko Villavicencio-Carranza, Ricardo J Ayala-García, Carlos A Castro-Callirgos, L. González-Hernández, Eduardo F Bernales-Salas, Johanna C Coacalla-Guerra, Cynthia D Salinas-Herrera, L. Nicolosi, Mauro Basconcel, J. B. Byrd, Tiffany Sharkoski, Luis E Bendezú-Huasasquiche, J. Chittams, Daniel L. Edmonston, C. Vasquez, J. Chirinos	7	2021	7 🐜